Related Experiment Video
Updated: May 22, 2026
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Radiolabeled small molecule inhibitors of VEGFR - recent advances
1Institute of Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf, POB 510119, D-01314 Dresden, Germany. t.kniess@hzdr.de
Abstract:
The vascular endothelial growth factor (VEGF) is a key regulator of neovascularization and an elevated level of VEGF is known to correlate with increased metastatic invasion. Anti-angiogenic therapies focus on targeted inhibition of overexpressed growth factors with the aim of suppressing tumor proliferation, one approach is the attempt to block the intracellular tyrosine kinase at the adenosine triphosphate (ATP) binding site with small molecule inhibitors. For most effective treatment these targeted tumor therapies are accompanied with a more sensitive need for dose optimization and monitoring the therapeutic response. Direct non-invasive molecular imaging of tumor vascularization and of the angiogenic process in vivo would facilitate the selection of patients and help to evaluate the efficacy of an anti-angiogenic therapy. Radionuclide-based imaging technologies like PET and SPECT are progressively affecting the clinical diagnosis and treatment of cancer. A non-invasive and a reliable quantitative method to determine in vivo the levels of VEGFR expression using radiolabeled small molecules would help to develop a customized VEGFR-targeted chemotherapy. This review will give an overview on radiolabeled derivatives of small molecule VEGFR inhibitors basing on lead structures that have been approved or have reached clinical trials. It is covering aspects of the radiosynthesis as well the results of radiopharmacological and biological evaluation.
Insights
Radiolabeled small molecule inhibitors targeting vascular endothelial growth factor receptor (VEGFR) enable non-invasive imaging for optimizing anti-angiogenic cancer therapies. This approach aids patient selection and monitors treatment efficacy by quantifying VEGFR expression in vivo.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Vascular endothelial growth factor (VEGF) drives neovascularization and metastasis; elevated levels correlate with cancer progression.
- Anti-angiogenic therapies target VEGF pathway, requiring precise dose optimization and response monitoring.
- Non-invasive in vivo imaging of tumor vascularization and angiogenesis is crucial for personalized cancer treatment.
Purpose of the Study:
- To review radiolabeled small molecule VEGFR inhibitors for non-invasive imaging.
- To explore their potential in patient selection and therapeutic response evaluation.
- To cover radiosynthesis and radiopharmacological data of these inhibitors.
Main Methods:
- Review of literature on radiolabeled small molecule VEGFR inhibitors.
- Focus on compounds based on approved or clinically trialed lead structures.
- Inclusion of radiosynthesis and radiopharmacological evaluation data.
Main Results:
- Radiolabeled small molecules offer a quantitative method for in vivo VEGFR expression assessment.
- These agents facilitate non-invasive imaging of tumor angiogenesis.
- Data on radiosynthesis and biological evaluation of various radiolabeled VEGFR inhibitors are presented.
Conclusions:
- Radiolabeled VEGFR inhibitors are promising tools for personalized anti-angiogenic cancer therapy.
- Non-invasive molecular imaging can guide patient selection and treatment monitoring.
- Further development in this area can enhance the efficacy of targeted cancer treatments.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis